Haemonetics Performance Comparison

Loading chart data...

Stock Range

Today's Range

Low: $76.45 High: $79.93
on July 9, 2025

52 Week Range

Low: $55.30 High: $94.99
on April 9, 2025
on November 12, 2024

All-Time High: $142.11 on February 8, 2021

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $3.7B
EPS i N/A
P/E Ratio (TTM) i 23.42
Forward P/E i 14.52
P/B Ratio i 4.55
PEG Ratio i 14.52
Div. Yield i N/A
ROE i 18.83%
Beta i N/A
Debt to Equity i 156.35

Financial Highlights

Profitability

Gross Margin i 58.39%
Operating Margin i N/A
Profit Margin i N/A

Returns and Earnings

Return on Assets (TTM) i N/A
Return on Equity (TTM) i 18.83%
EBITDA i N/A
Net Income (TTM) i N/A

Growth

Revenue (TTM) i
Revenue Per Share (TTM) i
Quarterly Revenue Growth i
Quarterly Earnings Growth i

Peer Performance Comparison

Performance comparison table showing returns for peer companies over various time periods
CompanyMarket Cap1W1M3M6MYTD1Y3Y5Y
Haemonetics HAE 3.72B Mid-cap1.68%8.19%27.02%1.11%-1.12%-16.13%18.54%-17.42%
Abbott Laboratories ABT 233.32B Mega-cap-0.66%-0.13%4.86%18.62%17.44%27.96%22.55%34.37%
Boston Scientific BSX 154.34B Large-cap-0.65%2.92%6.40%8.52%15.19%31.82%172.73%171.57%
Masimo MASI 8.85B Mid-cap-3.46%-3.76%0.51%-0.61%-1.87%45.01%26.98%-30.90%
Globus Medical GMED 7.70B Mid-cap-5.38%-5.02%-22.85%-34.18%-29.96%-20.36%0.46%16.75%
Bio-Rad BIO.B 7.10B Mid-cap0.00%0.00%3.34%-26.66%-23.19%-11.77%-49.77%-49.64%

Ownership & Short Interest

Insider Ownership i 1.11%
Institutional Ownership i 118.44%
Shares Short i 4M
Short Ratio i 8.33
Short % of Shares Outstanding i 11.24%
Average 10-Day Volume i 600K
Average 90-Day Volume i 555K

Haemonetics Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Haemonetics would have performed over time.

$
If not specified, the latest available data will be used

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is HAE's 52-week high and low?

In the last 52 weeks, Haemonetics reached a high of $94.99 (on November 12, 2024) and a low of $55.30 (on April 9, 2025).

What is the market cap and P/E ratio for HAE?

Curious about Haemonetics's size and valuation? Its market capitalization stands at 3.72B. When it comes to valuation, the P/E ratio (trailing twelve months) is 23.42, and the forward P/E (looking ahead) is 14.52.

Does HAE pay dividends? If so, what's the yield?

As for dividends, Haemonetics isn't currently offering a significant yield, or that specific data isn't available right now.

Who are Haemonetics's main competitors or similar companies to consider before investing?

When looking at Haemonetics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

CompanyMkt CapSectorIndustry1Y Return3Y Return
Abbott Laboratories
ABT
233.32BHealthcareMedical Devices27.96%22.55%
Boston Scientific
BSX
154.34BHealthcareMedical Devices31.82%172.73%
Masimo
MASI
8.85BHealthcareMedical Devices45.01%26.98%
Globus Medical
GMED
7.70BHealthcareMedical Devices-20.36%0.46%
Bio-Rad
BIO.B
7.10BHealthcareMedical Devices-11.77%-49.77%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Haemonetics Corporation? (e.g., ROE, Debt/Equity)

To get a sense of Haemonetics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.83%, the Debt to Equity ratio from the most recent quarter is 156.35, and its Gross Profit Margin stands at 58.39%.

What is the recent revenue and earnings growth for HAE?

Looking at Haemonetics's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by -3.70%, and quarterly earnings saw a YoY growth of 184.70%.

How much of HAE stock is held by insiders and institutions?

Wondering who owns Haemonetics stock? Company insiders (like executives and directors) hold about 1.11% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 118.44%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.